Clinical trials of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II (Ang II) receptor blockers (ARBs) supported the experimental findings and were shown to retard the progression of renal disease [10,11]. The gene discussed is ACE; the disease is kidney disorder.